BioNTech Bets Its Future on Seoul as the Street Demands Proof

BioNTech presents pumitamig-ADC lung cancer data in Seoul as BMO cuts it to Market Perform and CEO Ugur Sahin keeps selling shares.

BioNTech has spent the better part of a year trying to convince investors it is no longer a COVID company. This week, it gets its most visible stage yet — and its most unforgiving audience.

From September 12 to 15, the German biotech presents fresh clinical data at the IASLC World Conference on Lung Cancer in Seoul. The centerpiece is a late-breaking oral presentation detailing, for the first time anywhere, combination results from a study pairing pumitamig with the antibody-drug conjugate elfetabart drozuntecan in lung cancer. According to the company, it marks the first time a PD-(L)1xVEGF bispecific immunomodulator has been combined with an ADC in this tumor type. Updated survival data from the Phase 3 PRESERVE-003 trial in squamous non-small cell lung cancer round out the disclosure, alongside progress on the second lead candidate, gotistobart, and BioNTech's mRNA-based immunotherapy programs.

Pumitamig is being developed jointly with Bristol Myers Squibb. The readouts represent, in scientific terms, exactly the kind of milestone a pipeline-driven biotech wants to showcase.

A Bruising Run Into the Spotlight

The timing, however, is anything but comfortable. Roughly two weeks before the conference, BioNTech and Genentech had to halt a Phase 2 trial of autogene cevumeran in resectable colorectal cancer after an independent data monitoring committee flagged an imbalance in overall survival between treatment arms. No new safety signals emerged, but the damage was done: shares fell more than 7 percent on the news. It was the second major blow in a matter of weeks, following a quarterly report that laid bare a sharp revenue decline and forced the company to cut its full-year guidance.

That backdrop explains why Seoul matters more than a typical scientific meeting. The company needs the oncology narrative to hold — and the market has grown measurably more cautious about BioNTech's cancer promises.

BMO Steps Back

Wall Street's patience showed its limits on September 8, when BMO Capital Markets downgraded the stock from "Outperform" to "Market Perform" and slashed its price target from $128 to $105. The reasoning went beyond the pipeline setbacks: Comirnaty's COVID vaccine business is contracting faster than the bank had modeled. Just as important, BMO noted a lack of convincing "de-risking" data on pumitamig — evidence that may not arrive until 2028 at the earliest. Seoul, in other words, offers early signals, but the decisive proof remains years away.

Sahin's Steady Selling

While the science takes center stage in Korea, a quieter storyline continues in Germany. CEO Ugur Sahin has kept selling shares under a Rule 10b5-1 trading plan established in June. In early September he offloaded a total of 76,500 shares across two days at prices around $103, followed by further tranches at roughly $96 to $99, including sales on September 8 and 9 at between about $97 and $99.

Such automated plans are legally unremarkable and say little on their own about a company's health. Accumulated over weeks and tens of thousands of shares, though, they color perceptions — particularly as Sahin and co-founder Özlem Türeci prepare to depart for a new, independent mRNA venture, with the company still searching internally for a new chief medical officer.

A Leadership Handover and a Legal Fight

The succession plan is already public: Guido Oelkers, joining from Sobi, takes over as CEO on February 1, 2027, while Sahin and Türeci are set to leave for their new mRNA company by the end of 2026. Adding to the mix, Arbutus Biopharma and Genevant Sciences filed multiple patent suits in July over the lipid nanoparticle technology behind Comirnaty, targeting Pfizer and BioNTech in Canada and before the Unified Patent Court. BioNTech says it has strong defenses and intends to fight vigorously, though disputes of this kind typically drag on for years.

Where the Stock Stands

The market's verdict so far is one of ambivalence. BioNTech closed Friday at EUR 83.65, roughly flat on the day but down 6.4 percent over the week — a decline that tracks with the colorectal trial halt and the BMO downgrade. The shares sit about 21 percent below their 52-week high of EUR 105.80, reached back in January, yet remain up 2.8 percent year to date. Market capitalization stands at just over EUR 21 billion — a modest figure for a company positioning itself as an oncology pioneer.

That tension captures the moment precisely. BioNTech is trying to shed its pandemic-winner skin while its founding leadership prepares to exit, fresh litigation looms, and insiders sell on schedule. Seoul supplies the scientific case for the next chapter. Whether the market buys it is a question the conference itself cannot answer.